The global Allergy Immunotherapy Market Size is expected to reach USD 5.74 Billion by 2033. The global Allergy Immunotherapy industry size accounted for USD 2.36 billion in 2023 and is expected to expand at a compound annual growth rate (CAGR) of 9.04% from 2023 to 2033. Allergy immunotherapy, also known as allergen immunotherapy or allergy shots, is a medical treatment that aims to desensitize a person’s immune system to specific allergens, which are substances that trigger an allergic reaction. It involves administering gradually increasing doses of the allergen to the person over a while, usually several months to several years, to reduce or eliminate their allergic symptoms. The principle behind allergy immunotherapy is to expose the immune system to the allergen in a controlled and gradual manner, allowing the body to build up a tolerance to the allergen over time. This can help the person’s immune system to become less sensitive to the allergen, thereby reducing the severity of their allergic reactions or preventing them altogether.
COVID-19 Impact Analysis
The impact of the COVID-19 pandemic on the allergy immunotherapy market may be complex and multifaceted and could vary depending on various factors such as region, healthcare infrastructure, and economic conditions. While the pandemic has undoubtedly brought unprecedented challenges to the healthcare industry, including disruptions in medical services and changes in patient behaviors, it may have moderate effects on the allergy immunotherapy market. The increased awareness of respiratory health and the importance of maintaining a strong immune system during the pandemic may have led to a greater emphasis on managing allergies, including seeking allergy immunotherapy as a long-term solution for allergy sufferers. With people spending more time indoors and being exposed to indoor allergens, such as dust mites and pet dander, the demand for allergy immunotherapy could potentially surge.
Allergy Immunotherapy Market Dynamics
The major factors that have impacted the growth of Allergy Immunotherapy are as follows:
Ø Increasing prevalence of allergic conditions
The increasing prevalence of allergic conditions is a significant driving factor for the growth of the Allergy Immunotherapy market. Allergic conditions, such as allergic rhinitis, allergic asthma, atopic dermatitis, and food allergies, are becoming more common globally, affecting millions of people worldwide. The exact reasons for the increasing prevalence of allergies are complex and multifactorial, but factors such as changing lifestyles, environmental exposures, genetics, and urbanization are believed to play a role. As the prevalence of allergic conditions continues to rise, the demand for effective treatment options like allergy immunotherapy is expected to increase as well. This is driving the growth of the Allergy Immunotherapy market as healthcare providers and patients seek long-term solutions to manage allergies effectively. Additionally, the increasing awareness among healthcare providers and patients about the benefits of allergy immunotherapy as a viable treatment option for allergies is further contributing to its adoption and market growth.
Ø High cost of immunotherapy
Allergy immunotherapy can be expensive, involving multiple doses over an extended time. The cost of immunotherapy can vary depending on the type (subcutaneous immunotherapy or sublingual immunotherapy), duration, and frequency of treatment, as well as geographical location and healthcare settings. The high cost of immunotherapy may pose a barrier to accessibility for some patients, particularly those with limited financial resources or inadequate insurance coverage.
⮚ Increasing awareness and education
There is a growing awareness among healthcare providers, patients, and caregivers about the benefits of allergy immunotherapy as a long-term treatment option for allergies. Increased education and awareness campaigns by healthcare organizations, patient advocacy groups, and pharmaceutical companies can further drive awareness about the efficacy, safety, and availability of immunotherapy. Improved awareness and education can lead to increased patient demand for allergy immunotherapy, creating opportunities for market growth.
Allergy Immunotherapy Segment Overview
By Treatment Type
Based on the Treatment Type, the market is segmented based on Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT). During the projection period, the Subcutaneous Immunotherapy (SCIT) segment is expected to hold the largest market share. SCIT involves injecting allergen extracts into the subcutaneous layer of the skin, typically in the upper arm, with gradually increasing doses over time. This helps to desensitize the immune system to specific allergens and reduce allergic symptoms. SCIT has been proven to be effective in managing allergic rhinitis, allergic asthma, and other allergic conditions.
By Allergy Type
Based on Allergy Type, the market has been divided into Allergic Rhinitis, Allergic Asthma, and Others. The Allergic Asthma segment is expected to hold the largest market share. Allergic asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways in response to allergens, leading to symptoms such as wheezing, coughing, chest tightness, and shortness of breath. Allergy immunotherapy, also known as allergy shots or allergen-specific immunotherapy, is a type of treatment that aims to desensitize the immune system to allergens by gradually exposing the patient to increasing doses of the allergen. This helps the immune system to build tolerance and reduce the severity of allergic reactions.
By Distribution Channel
Based on Distribution Channel, the market has been divided into Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy. The Hospital Pharmacy segment is expected to hold the largest market share. Hospital pharmacies are an important channel for the distribution of pharmaceutical products, including allergy immunotherapy treatments. Allergy immunotherapy may be prescribed and administered in hospital settings, particularly for patients with severe allergic conditions or those who require close medical supervision during treatment.
Global Allergy Immunotherapy Market Share, by Segmentation
Global Allergy Immunotherapy Market Regional Analysis
Based on region, the global MHealth market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America is projected to dominate the use of the market followed by the Asia-Pacific and Europe regions.
North America Market
North America has been a significant market for the Allergy Immunotherapy market. The region has a high prevalence of allergic conditions, such as allergic rhinitis, allergic asthma, and other related allergies, which drive the demand for allergy immunotherapy treatments. Additionally, North America has a well-established healthcare infrastructure, advanced research and development capabilities, and a favorable reimbursement environment, which further supports the growth of the Allergy Immunotherapy market in the region. Furthermore, there is a growing awareness among healthcare providers and patients about the benefits of allergy immunotherapy as a long-term treatment option for allergies, which has contributed to the market growth in North America.
The Asia-Pacific region is projected to be a prominent growth market for the Allergy Immunotherapy market. There is increasing awareness among healthcare providers and patients in the Asia-Pacific region about the benefits of allergy immunotherapy as a long-term treatment option for allergies. This is leading to increased adoption of immunotherapy as a part of the comprehensive management of allergic conditions. The Asia-Pacific region is experiencing a rising prevalence of allergic conditions, including allergic rhinitis, allergic asthma, and food allergies, among others. This is attributed to changing lifestyles, environmental factors, and urbanization, which are driving the demand for effective allergy management options such as immunotherapy.
The market comprises tier-1, tier-2, and local players. With their wide product portfolios, tier-1 and tier-2 players have a global reach. Since their strategic innovations and broad regional presence, companies such as Adamis Pharmaceuticals Corporation, Merck KGaA, Stallergenes Greer, and Allergy Therapeutics lead the global Allergy Immunotherapy business. To increase their market position and attract a wide consumer base, the businesses are employing various strategies, such as growth, product releases, and alliances.
- ASIT Biotech
- Mylan N.V.
- Adamis Pharmaceuticals Corporation
- Merck KGaA
- Stallergenes Greer plc
- Aravax Pty Ltd
- HollisterStier Allergy
- DBV Technologies
July 2022: Stallergenes Greer stated significant data on the considerable impact of sublingual liquid allergen immunotherapy (AIT) on the onset and exacerbation of asthma in individuals with allergic rhinitis.
March 2022: Aravax Pty Ltd announced the submission of an investigational new drug (IND) application for PVX108, a next-generation immunotherapy for the treatment of peanut allergy.
Scope of the Report
Global Allergy Immunotherapy Market, by Treatment Type
- Subcutaneous Immunotherapy (SCIT)
- Sublingual Immunotherapy (SLIT)
Global Allergy Immunotherapy Market, by Allergy Type
- Allergic rhinitis
- Allergic asthma
Global Allergy Immunotherapy Market, by Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Allergy Immunotherapy Market, by Region
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
|Market Size||2033: $5.74 Billion|
|CAGR||9.04% CAGR (2023-2033)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Key Segmentations||Treatment Type, Allergy Type, Distribution Channel|
|Geographies Covered||North America, Europe, Asia-Pacific, Latin America, Middle East, Africa|
|Key Vendors||ASIT Biotech, Circassia, Mylan N.V., Adamis Pharmaceuticals Corporation, Merck KGaA, Stallergenes Greer plc, Aravax Pty Ltd, HollisterStier Allergy, LETIPharma, DBV Technologies|
|Key Market Opportunities||Increasing awareness and education|
|Key Market Drivers||Increasing prevalence of allergic conditions|
REPORT CONTENT BRIEF:
- High-level analysis of the current and future Allergy Immunotherapy market trends and opportunities
- Detailed analysis of current market drivers, restraining factors, and opportunities in the future
- Allergy Immunotherapy market historical market size for the year 2021, and forecast from 2023 to 2033
- Allergy Immunotherapy market share analysis at each product level
- Competitor analysis with a detailed insight into its product segment, financial strength, and strategies adopted.
- Identifies key strategies adopted including product launches and developments, mergers and acquisitions, joint ventures, collaborations, and partnerships as well as funding taken and investment done, among others.
- To identify and understand the various factors involved in the global Allergy Immunotherapy market affected by the pandemic
- To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company’s past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.
Frequently Asked Questions (FAQ)
- What is the study period of this market?
- The study period of the global Allergy Immunotherapy market is 2022- 2033
- What is the growth rate of the global Allergy Immunotherapy market?
- The global Allergy Immunotherapy market is growing at a CAGR of ~ 04% over the next 10 years
- Which region has the highest growth rate in the market of Allergy Immunotherapy?
- Asia Pacific is expected to register the highest CAGR during 2023-2033
- Which region has the largest share of the global Allergy Immunotherapy market?
- North America holds the largest share in 2022
- Who are the key players in the global Allergy Immunotherapy market?
- ASIT Biotech, Circassia, Mylan N.V., Adamis Pharmaceuticals Corporation, Merck KGaA, Stallergenes Greer plc, Aravax Pty Ltd, HollisterStier Allergy, LETIPharma, DBV Technologies are the major companies operating in the market.
- Do you offer Post Sale Support?
- Yes, we offer 16 hours of analyst support to solve the queries
- Do you sell particular sections of a report?
Yes, we provide regional as well as country-level reports. Other than this we also provide a sectional report. Please get in contact with our sales representatives.